Janux Therapeutics, Inc. JANX 深 沪
等待开盘 08-04 09:30:00 美东时间
23.56
-0.455
-1.89%
华盛通- 最 高24.415
- 今 开23.79
- 成交量 61.20万股
- 最 低 23.31
- 昨 收 24.015
- 总市值 13.94亿
- 52周最高 71.71
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 22.48
- 委 比 1.06%
- 总股本 5917.52万
- 历史最高 71.71
- 量 比 0.66
- 振 幅 4.60%
- 历史最低 5.65
- 每 手 1
- 风险率 11.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Janux Therapeutics Showcases Advancements In TRACTr, TRACIr, And ARM Platforms Ahead Of 2026 Trials At R&D Day Webcast
PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses.TROP2-TRACTr adds first-in-class
07-25 04:28
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
07-16 01:35
Raymond James Initiates Coverage On Janux Therapeutics with Outperform Rating, Announces Price Target of $65
Raymond James analyst Sean McCutcheon initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Outperform rating and announces Price Target of $65.
07-11 21:03
SA Asks: Which oncology companies are attractive M&A targets?
Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology (NASDA...
05-31 03:00
Janux Therapeutics Initiates Phase 1b Expansion Studies In Ongoing ENGAGER-PSMA-01 Trial
Phase 1b expansion study initiated in taxane-naïve mCRPC patientsUpdated data from Phase 1a dose escalation support initiation of Phase 1b dose expansionUpdates on JANX007 and JANX008 expected in the second half of
05-05 20:37
Analysts’ Top Healthcare Picks: Xenon (XENE), Janux Therapeutics Inc (JANX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
03-06 21:00
美股大行评级 | Piper Sandler：上调ACNB Corp评级至"超配"，目标价从37美元升至50美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1103601922058588161.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持Rocket Pharmaceuticals(RCKT)"跑赢大市"评级，目标价从51美元升至52美元</p> <p>• HC Wainwright & Co.：维持Revolution Medici
03-04 08:54
美股大行评级 | CJS Securities：上调艾伦建材评级至"跑赢大市"，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1102515815739830272.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Denali Therapeutics(DNLI)"买入"评级，目标价从80美元升至87美元</p> <p>• HC Wainwright & Co.：维持Car
03-01 09:21
Scotiabank Maintains Sector Perform on Janux Therapeutics, Lowers Price Target to $41
Scotiabank analyst George Farmer maintains Janux Therapeutics (NASDAQ:JANX) with a Sector Perform and lowers the price target from $62 to $41.
03-01 07:36
Janux Therapeutics GAAP EPS of -$0.36 beats by $0.07
Janux Therapeutics press release (NASDAQ:JANX): Q4 GAAP EPS of -$0.36 beats by $0.07. Shares +1.53% AH. More on Janux Therapeutics Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data Ja...
02-28 06:40
